

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents  
Washington, D.C. 20231 on January 16, 2001.

*Frank C. Eisenschenk*

Frank C. Eisenschenk, Ph.D., Patent Attorney



1631-1  
NE  
19/C  
1/NE.  
AMENDMENT UNDER 37 C.F.R. §1.116  
Examining Group 1644  
Patent Application  
Docket No. SPO-103  
Serial No. 09/142,524

RECEIVED

JAN 23 2001

TECH CENTER 1600/2600

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : M. DiBrino, Ph.D.  
Art Unit : 1644  
Applicants : Toshio Sone, Akinori Kume, Kazuo Dairiki, Akiko Iwama, Kohsuke Kino  
Serial No : 09/142,524  
Filed : September 9, 1998  
For : Peptide-Based Immunotherapeutic Agent for Treating Allergic Diseases

Box AF  
Assistant Commissioner for Patents  
Washington, D.C. 20231

AMENDMENT AFTER FINAL UNDER 37 CFR §1.116

Sir:

A Petition and Fee for a two-month Extension of Time through and including January 16, 2001, accompanies this Amendment.

In response to the Office Action dated August 16, 2000, please amend the above-referenced application as follows:

In the Specification

Page 3, line 6: Please change "interferon 2" to -- interleukin 2 --.

Page 3, line 6: Please change "lymphotoxin" to -- tumor necrosis factor β --.

Page 7, lines 23: Please change "(Amb a 1, Amb a 2, Amb a 5, Amb t 5, Amb p 5)" to -- or Ambrosia artemisiifolia (Amb a 1, Amb a 2, Amb a 5), Ambrosia trifida (Amb t 5), Ambrosia psilostachya (Amb p 5) --.

Page 8, line 1: Please change "mountain cedar" to -- Juniper sabinooides --.

Do not enter  
2/12/01